Steve M. Sabus - 31 May 2022 Form 4 Insider Report for Turning Point Therapeutics, Inc.

Role
SVP & Chief Commercial Officer
Signature
/s/ Brian Sun, Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
31 May 2022
Net transactions value
$0
Form type
4
Filing time
01 Jun 2022, 17:02:36 UTC
Next filing
17 Aug 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TPTX Common Stock Award $0 +36,667 $0.000000 36,667 31 May 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TPTX Stock Option (right to buy) Award $0 +165,000 $0.000000 165,000 31 May 2022 Common Stock 165,000 $35.37 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents restricted stock unit award granted under the Issuer's 2019 Equity Incentive Plan.
F2 25% of the shares vest on May 31, 2023 and 1/48th of the shares vest monthly thereafter over the next three years.